|
US5198425A
|
|
Inhibitors of bacterial ribonucleotide reductase
|
|
US5242946A
|
|
Treating herpes Viral infections
|
|
AU7827491A
|
|
Antiherpes peptide derivatives having a 1,4-dioxo-c4n-terminus
|
|
CA2036413A1
|
|
Hiv protease inhibitors
|
|
CA2036398A1
|
|
Hiv protease inhibiting agents
|
|
CA2036397A1
|
|
Hiv protease inhibitors containing derived amino acid units
|
|
CA2033447A1
|
|
Synergistic combination for treating herpes infections
|
|
AU5877590A
|
|
Antiherpes pentapeptide derivatives having a substituted aspartic acid side chain
|
|
CA2019006A1
|
|
Antiherpes tetrapeptide derivatives having a cycloalkyl substituted aspartic acid side chain
|
|
CA2019005A1
|
|
Antiherpes pentapeptide derivatives having a cycloalkyl substituted aspartic acid side chain
|
|
CA2018801A1
|
|
Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus
|
|
CA1340911C
|
|
Antiherpes cyclic peptides
|
|
CA1340683C
|
|
Antiherpes pentapeptides having a substituted aspartic acid side chain
|
|
CA1340682C
|
|
Antiviral peptides having a 2-oxoalkyl amino acid side chain
|
|
CA1340681C
|
|
Antiherpes tetrapeptides having a substituted aspartic acid side chain
|
|
CA1340684C
|
|
Antiherpes pentapeptides
|
|
US5126326A
|
|
Enzyme inhibiting peptide derivatives
|
|
US5212157A
|
|
Enzyme inhibitors
|
|
CA1324086C
|
|
Methods and compositions for combatting herpes viruses
|
|
CA1323574C
|
|
Treating herpes viral infections
|
